Ryanair Holdings plc vs Viatris Inc — how do they compare? Ryanair Holdings plc trades at $52.96 (market cap $27.11B), while Viatris Inc trades at $17.5 (market cap $20.03B). The key difference: Ryanair Holdings plc is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Ryanair Holdings plc for 72 Days and Viatris Inc for 57 Days on average.
| RYAAY | VTRS | |
|---|---|---|
Market Cap | $27.11B | $20.03B |
Volume | 2,427,380 | 14,109,977 |
Sector | Industrials | Health |
52-Week High | $73.82 | $18.27 |
52-Week Low | $51.95 | $9.74 |
Typical Hold Time | 72 Days | 57 Days |
Enterprise Value | $24.18B | $32.15B |
Dividend Yield | 1.66% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $53.1, down 5.18% on the day, reflecting a bearish technical signal amid mixed earnings performance. The company maintains strong profitability with a 12.13% net income margin and 22.41% ROE, while valuation metrics like a P/E of 13.43 appear attractive. Recent news highlights CEO commentary on Boeing MAX 10 certification delays and concerns over rising fuel costs impacting future airfares.
The stock presents a value opportunity given its low valuation multiples and robust cash flow generation, but faces near-term headwinds from volatile fuel prices and a lowered FY27 traffic outlook. Analyst consensus remains moderately bullish, though technical indicators suggest caution. Key risks include oil price sensitivity and competitive pressures in the European airline sector.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Trailing returns across standard periods
Latest headlines on both assets
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →